What's preventing us from preventing type 2 diabetes?

New England Journal of Medicine

Volumn 367, Issue 13, 2012, Pages 1177-1179

  Fradkin, Judith E ^a   Roberts, B Tibor ^a   Rodgers, Griffin P ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PLACEBO;

CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES CONTROL; DISEASE DURATION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PATIENT COUNSELING; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY;

EID: 84866773055     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1208169     Document Type: Article

References (5)

1. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or met-formin. N Engl J Med 2002;346:393-403.
2. Idem. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723-30.
3. Centers for Disease Control and Prevention. National Diabetes Prevention Program (http://www.cdc.gov/diabetes/prevention/).
4. The DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-76.
5. Huang ES, Basu A, O'Grady MJ, Capretta JC. Using clinical information to project federal health care spending. Health Aff (Millwood) 2009;28:w978-w990.